Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now ...
Arc Institute, Gladstone Institutes, and University of California, San Francisco, scientists have developed an epigenetic editing platform that enables safe modification of multiple genes in primary ...
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year ...
The outspoken longevity scientist David Sinclair has been predicting that one day, you’ll go to the doctor and get a ...
Lactate, once considered a metabolic waste product, is now recognized as a key regulator of cellular homeostasis and disease progression. In gynecological malignancies-including ovarian, cervical, and ...
NewLimit Series C raises $435M led by Founders Fund as Armstrong-backed startup moves epigenetic therapies toward human ...
Image: CC] On Tuesday, Boston-based biotech startup Life Biosciences announced the dosing of its first patient with a cellular reprogramming injection, designed to reverse age-re ...
Armed with a fully subscribed $80 million series D round, Life Biosciences Inc. is making progress with its lead candidate, ER-100, which is in phase I trials testing its theory on reversing the ...
The Hearty Soul on MSN
The world's first reverse aging drug was just injected into a human
The world's first reverse aging drug, ER-100, was injected into a human on June 9, 2026 The post The World’s First ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results